AI Article Synopsis

Article Abstract

We present experience of using anti-thymocytic immunoglobulin (ATG) in complex therapy of patients with extensive secondary peritonitis at the age of 29-83 years. The research was based on 60 patient cases: 29 (48%) of whom were given anti-thymocytic immunoglobulin (ATG) Antilymfolin in post operative period and 31 patient of the control group who did not receive immunomodulating therapy within the complex treatment. The received data clearly demonstrates the effectiveness of anti-thymocytic immunoglobulin (ATG) usage for normalization of innate immunity indices and inflammation reduction. Immunostimulating effect in patients given anti-thymocytic immunoglobulin (ATG) could be seen on the fourth day of the threatment. The drug is equally effective in patients of young and middle age as well as in patients of elderly and senility age. The positive influence of anti-thymocytic immunoglobulin (ATG) on inflammation is shown with the reduction of CRP, gamma-globuline, alpha1-protein fraction serum levels normalization. The use of Antilymfolin induces the regression of inflammation and apparently improves the quality and duration of treatment and rehabilitation.

Download full-text PDF

Source

Publication Analysis

Top Keywords

anti-thymocytic immunoglobulin
20
immunoglobulin atg
20
immunomodulating therapy
8
therapy complex
8
complex treatment
8
secondary peritonitis
8
inflammation reduction
8
patients
5
anti-thymocytic
5
immunoglobulin
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!